Association between exposure to metformin and risk of MPN according to duration of metformin exposure among individuals without registered markers of diabetes
| Subgroup . | Cases, n . | Controls, n . | OR∗ (95% CI) . | Adjusted OR† (95% CI) . |
|---|---|---|---|---|
| Exposure | ||||
| Never-use | 3490 | 17 716 | 1.0 (reference) | 1.0 (reference) |
| Ever-use | 132 | 394 | 1.71 (1.40-2.09) | 1.63 (1.33-2.01) |
| Long-term use (≥5 y) | 5 | 15 | 1.76 (0.64-4.90) | 1.58 (0.56-4.45) |
| Subgroup . | Cases, n . | Controls, n . | OR∗ (95% CI) . | Adjusted OR† (95% CI) . |
|---|---|---|---|---|
| Exposure | ||||
| Never-use | 3490 | 17 716 | 1.0 (reference) | 1.0 (reference) |
| Ever-use | 132 | 394 | 1.71 (1.40-2.09) | 1.63 (1.33-2.01) |
| Long-term use (≥5 y) | 5 | 15 | 1.76 (0.64-4.90) | 1.58 (0.56-4.45) |
NSAIDs, nonsteroidal anti-inflammatory drugs.
Adjusted for age, sex, and calendar time.
Adjusted for age, sex, and calendar time, in addition to (1) education level (primary school, high school, short/middle long education, and long education); (2) Charlson comorbidity index (0, 1, and ≥2); (3) previous use of aspirin, other NSAIDs, alendronate, immunosuppressants, and statins; and (4) previous history of alcohol related diagnoses, overweight and obesity-related diagnoses, chronic obstructive pulmonary disease, and autoimmune disease.